Lactobacillus acidophilus ATCC 4356

Lactobacillus acidophilus ATCC 4356 is a well-characterized probiotic strain that produces lactic acid, hydrogen peroxide, and bacteriocins to modulate gut microbiota and systemic inflammation. Its primary mechanisms involve reducing oxidative stress markers and improving cholesterol metabolism through bile salt hydrolase activity and antioxidant enzyme upregulation.

Origin & History

Lactobacillus acidophilus ATCC 4356 is a specific probiotic bacterial strain originally isolated from the human gastrointestinal tract and deposited in the American Type Culture Collection. This gram-positive, rod-shaped bacterium is cultured in laboratory media such as MRS broth and serves as a clinical probiotic strain known for producing bacteriocins and modulating gut microbiota.

Historical & Cultural Context

No historical or traditional medicine use is documented for Lactobacillus acidophilus ATCC 4356, as it is a modern laboratory-deposited strain without ties to traditional systems like Ayurveda, TCM, or folk medicine. The strain exists solely as a research and clinical probiotic developed through modern microbiology.

Health Benefits

• May protect against kidney injury by reducing oxidative stress and inflammation (preliminary evidence from mouse models)
• Shows potential for reducing atherosclerosis progression and improving cholesterol metabolism (animal studies only)
• Demonstrates antioxidant effects in diabetic conditions, particularly protecting testicular tissue (rat studies)
• Exhibits antimicrobial activity against pathogens including C. albicans and P. aeruginosa (in vitro and insect models)
• Supports beneficial gut microbiota balance by increasing Lactobacillus and Bifidobacterium populations (animal evidence)

How It Works

Lactobacillus acidophilus ATCC 4356 exerts antioxidant effects by upregulating superoxide dismutase (SOD) and catalase activity while reducing malondialdehyde (MDA) levels, a key marker of lipid peroxidation. The strain produces bile salt hydrolase (BSH), an enzyme that deconjugates bile acids in the gut, reducing cholesterol reabsorption and improving lipid profiles. Additionally, it modulates NF-κB signaling pathways to suppress pro-inflammatory cytokines such as TNF-α and IL-6, which are implicated in both atherosclerosis progression and kidney injury.

Scientific Research

All available evidence for Lactobacillus acidophilus ATCC 4356 comes from preclinical animal or in vitro models, with no human clinical trials identified. Key studies include mouse models of renal ischemia-reperfusion injury (PMID: 34046422), atherosclerosis in ApoE(-/-) mice (PMIDs: 25261526, 23747589), and rat diabetes models, demonstrating various protective effects through oral administration.

Clinical Summary

Current evidence for Lactobacillus acidophilus ATCC 4356 is derived almost exclusively from in vitro cell studies and murine (mouse) animal models, with no large-scale human randomized controlled trials specifically isolating this strain. In diabetic mouse models, supplementation reduced fasting blood glucose and MDA levels while increasing SOD activity. Atherosclerosis studies in ApoE-deficient mice showed reductions in aortic plaque area and improvements in LDL/HDL cholesterol ratios. The absence of human clinical trial data means efficacy and optimal dosing in humans cannot yet be confirmed, and findings should be interpreted cautiously.

Nutritional Profile

Lactobacillus acidophilus ATCC 4356 is a bacterial strain and does not contribute meaningful macronutrients or micronutrients in typical probiotic doses (1–10 billion CFU). Its primary bioactive contributions are metabolic byproducts: lactic acid (primary fermentation output, lowering local pH to ~3.5–4.5), bacteriocins including acidocin B and lactacin F (antimicrobial peptides), exopolysaccharides (immunomodulatory), and short-chain fatty acids (SCFAs) such as acetate produced in small quantities during fermentation. The strain produces bile salt hydrolase (BSH), which deconjugates bile acids and contributes to observed cholesterol-lowering effects — estimated LDL reduction of 5–10% in some human studies. It also generates hydrogen peroxide and lactic acid as antimicrobial agents. Surface-layer proteins (S-layer protein SlpA) contribute to gut epithelial adhesion and immune signaling via TLR2 pathways. B-vitamin synthesis (folate, B12 in trace amounts) has been documented in Lactobacillus genus broadly, though strain-specific output for ATCC 4356 is not precisely quantified. Bioavailability is highly dependent on survivability through gastric acid; encapsulated or enteric-coated delivery improves viable cell delivery to the colon by approximately 10–100 fold compared to unprotected formats.

Preparation & Dosage

No human dosage data is available for this strain. Animal studies used daily oral administration for 12-16 weeks in mice (dose-dependent effects observed but specific amounts not detailed), and 10^5 cells/larva in G. mellonella infection models. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Pairing with Bifidobacterium longum creates complementary colonization zones (small vs. large intestine) and additive SCFA production, while both strains synergistically upregulate IL-10 anti-inflammatory cytokines and downregulate NF-κB signaling, which may amplify the oxidative stress reduction seen in L. acidophilus ATCC 4356 animal studies. Prebiotic inulin or fructooligosaccharides (FOS) at 3–5g doses act as selective fermentation substrates that preferentially increase L. acidophilus CFU counts 2–4 fold in the gut, enhancing bile salt hydrolase activity and downstream cholesterol metabolism effects. Vitamin C (ascorbic acid, 250–500mg) and zinc (8–15mg) support the antioxidant pathways that L. acidophilus ATCC 4356 activates — ascorbic acid directly regenerates glutathione while the probiotic upregulates superoxide dismutase expression, creating an additive antioxidant defense particularly relevant to the documented testicular and renal protective effects. Omega-3 fatty acids (EPA/DHA, 1–2g) complement the atherosclerosis-relevant mechanisms by independently reducing triglycerides and VLDL while L. acidophilus ATCC 4356 targets LDL via BSH activity, covering multiple lipid metabolism pathways simultaneously.

Safety & Interactions

Lactobacillus acidophilus strains, including ATCC 4356, are generally recognized as safe (GRAS) by the FDA for healthy adults, with the most commonly reported side effects being mild gastrointestinal symptoms such as bloating or gas during initial use. Immunocompromised individuals, those with short bowel syndrome, or patients with central venous catheters face a rare but documented risk of bacteremia and should avoid probiotic use without medical supervision. Potential interactions exist with broad-spectrum antibiotics, which can significantly reduce strain viability and efficacy when taken simultaneously; spacing doses by at least two hours is advisable. Safety data during pregnancy and breastfeeding is limited, and consultation with a healthcare provider is recommended before use.